Connie Lesnick

798 total citations
23 papers, 390 citations indexed

About

Connie Lesnick is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Connie Lesnick has authored 23 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 11 papers in Pathology and Forensic Medicine and 7 papers in Immunology. Recurrent topics in Connie Lesnick's work include Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (7 papers) and Tea Polyphenols and Effects (4 papers). Connie Lesnick is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (7 papers) and Tea Polyphenols and Effects (4 papers). Connie Lesnick collaborates with scholars based in United States, Israel and Canada. Connie Lesnick's co-authors include Neil E. Kay, Tait D. Shanafelt, J.B. Derbyshire, Asish K. Ghosh, Timothy G. Call, José F. Leis, Betsy LaPlant, Charles Erlichman, Diane F. Jelinek and Deborah A. Bowen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Connie Lesnick

22 papers receiving 381 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Connie Lesnick 144 124 122 101 73 23 390
Caroline Aquino Moreira-Nunes 60 0.4× 295 2.4× 39 0.3× 25 0.2× 116 1.6× 68 541
Noushin Lotfi 29 0.2× 74 0.6× 111 0.9× 15 0.1× 48 0.7× 10 309
Maria Anele Romeo 57 0.4× 312 2.5× 126 1.0× 9 0.1× 211 2.9× 44 705
Sheng‐Ping Chou 75 0.5× 213 1.7× 93 0.8× 27 0.3× 319 4.4× 15 608
Rasa Ugenskienė 38 0.3× 170 1.4× 30 0.2× 14 0.1× 65 0.9× 54 378
Xiaoqiang Yan 113 0.8× 212 1.7× 138 1.1× 11 0.1× 80 1.1× 21 517
Emóke Nagy 22 0.2× 167 1.3× 58 0.5× 30 0.3× 15 0.2× 7 362
Hongli Xia 50 0.3× 136 1.1× 163 1.3× 20 0.2× 33 0.5× 42 405
Chunyan Hu 71 0.5× 279 2.3× 173 1.4× 11 0.1× 115 1.6× 24 614

Countries citing papers authored by Connie Lesnick

Since Specialization
Citations

This map shows the geographic impact of Connie Lesnick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Connie Lesnick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Connie Lesnick more than expected).

Fields of papers citing papers by Connie Lesnick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Connie Lesnick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Connie Lesnick. The network helps show where Connie Lesnick may publish in the future.

Co-authorship network of co-authors of Connie Lesnick

This figure shows the co-authorship network connecting the top 25 collaborators of Connie Lesnick. A scholar is included among the top collaborators of Connie Lesnick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Connie Lesnick. Connie Lesnick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lesnick, Connie, Yong Guo, Michael Bradshaw, et al.. (2024). Paraneoplastic Calmodulin Kinase‐Like Vesicle‐Associated Protein (CAMKV) Autoimmune Encephalitis. Annals of Neurology. 96(1). 21–33. 5 indexed citations
2.
Basal, Eati, et al.. (2024). Autoimmune Neurobeachin Cerebellar Ataxia. Movement Disorders. 39(12). 2271–2275.
3.
McKeon, Andrew, Connie Lesnick, Monica Buckley, et al.. (2023). Utility of Protein Microarrays for Detection of Classified and Novel Antibodies in Autoimmune Neurologic Disease. Neurology Neuroimmunology & Neuroinflammation. 10(5). 11 indexed citations
4.
Wang, Victoria, Tait D. Shanafelt, Connie Lesnick, et al.. (2023). Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial. Blood. 143(1). 57–63. 10 indexed citations
5.
Boddicker, Nicholas, Sara J. Achenbach, Sameer A. Parikh, et al.. (2022). Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis. Leukemia. 36(5). 1404–1407. 3 indexed citations
6.
Slager, Susan L., Sameer A. Parikh, Sara J. Achenbach, et al.. (2022). Progression and survival of MBL: a screening study of 10 139 individuals. Blood. 140(15). 1702–1709. 13 indexed citations
7.
Parikh, Sameer A., Kari G. Rabe, Neil E. Kay, et al.. (2021). The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. Blood. 138(2). 149–159. 23 indexed citations
8.
Slager, Susan L., Sameer A. Parikh, Sara J. Achenbach, et al.. (2021). Prevalence and Overall Survival of Low Count Monoclonal B-Cell Lymphocytosis (LC-MBL): A Screening Study of 8,297 Individuals from the Mayo Clinic Biobank. Blood. 138(Supplement 1). 2632–2632. 2 indexed citations
9.
10.
Larsen, Jeremy T., Tait D. Shanafelt, José F. Leis, et al.. (2017). Akt inhibitor MK‐2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study. American Journal of Hematology. 92(8). 759–763. 18 indexed citations
11.
Kay, Neil E., Paolo Strati, Betsy LaPlant, et al.. (2016). A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia. Oncotarget. 7(48). 78269–78280. 11 indexed citations
12.
13.
Sinha, Sutapa, Justin C. Boysen, Charla Secreto, et al.. (2015). Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clinical Cancer Research. 21(9). 2115–2126. 59 indexed citations
14.
Tsukamoto, Shuntaro, Yuhui Huang, Motofumi Kumazoe, et al.. (2015). Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKs. Molecular Cancer Therapeutics. 14(10). 2303–2312. 35 indexed citations
15.
Sinha, Sutapa, Justin C. Boysen, Charla Secreto, et al.. (2014). Targeted Inhibition of Axl Primes Chronic Lymphocytic Leukemia B-Cells for Apoptosis: Synergistic/Additive Effects in Combination with Bruton Tyrosine Kinase Inhibitors. Blood. 124(21). 1946–1946. 2 indexed citations
16.
Shanafelt, Tait D., Timothy G. Call, Clive S. Zent, et al.. (2012). Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer. 119(2). 363–370. 136 indexed citations
17.
Lesnick, Connie, Neil E. Kay, Betsy LaPlant, & Tait D. Shanafelt. (2009). The Green Tea Extract EGCG Demonstrates Synergist Activity against CLL B-Cells When Combined with Fludarabine and Chlorambucil.. Blood. 114(22). 3452–3452. 3 indexed citations
18.
Derbyshire, J.B. & Connie Lesnick. (1990). Hyporeactivity to Interferon Induction in Newborn Piglets. Journal of Interferon Research. 10(1). 47–53. 6 indexed citations
19.
Derbyshire, J.B. & Connie Lesnick. (1990). The effect of interferon induction in newborn piglets on the humoral immune response to oral vaccination with transmissible gastroenteritis virus. Veterinary Immunology and Immunopathology. 24(3). 227–234. 10 indexed citations
20.
Lesnick, Connie & J.B. Derbyshire. (1988). Activation of natural killer cells in newborn piglets by interferon induction. Veterinary Immunology and Immunopathology. 18(2). 109–117. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Caroline Aquino Moreira-Nunes Breakdown of academic impact, for papers by Noushin Lotfi Breakdown of academic impact, for papers by Maria Anele Romeo Breakdown of academic impact, for papers by Sheng‐Ping Chou Breakdown of academic impact, for papers by Rasa Ugenskienė Breakdown of academic impact, for papers by Xiaoqiang Yan Breakdown of academic impact, for papers by Emóke Nagy Breakdown of academic impact, for papers by Hongli Xia Breakdown of academic impact, for papers by Chunyan Hu
Rankless by CCL
2026